Alphamab Oncology
Alphamab Oncology's Waste Data Preview
In 2023, Alphamab Oncology conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Waste Generated | 0000000 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  a | 0000000 |
Total Waste Recovered | Copy/Paste is a PRO feature.  | 0000000 | Copy/Paste is a PRO feature. | 0000000 |
Total Hazardous Waste Generated | 0000000 | 0000000 | Copy/Paste is a PRO feature.  a | 0000000 |
Non-Hazardous Waste Disposed | Copy/Paste is a PRO feature. | Copy/Paste is a PRO feature. | 0000000 | 0000000 |
Verified Sources Behind Alphamab Oncology’s Waste Management Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alphamab Oncology’s data sources below and access millions more through our Disclosure Search.
Insights into Alphamab Oncology’s Generation of Hazardous and Non-Hazardous Waste
In 2023, Alphamab Oncology generated a total of 274 metric tonnes of waste.a
Of this amount, 98.9% of Alphamab Oncology's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.1.1% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Alphamab Oncology’s Hazardous vs Non-Hazardous Waste Over Time
- Total Non-Hazardous Waste Generated
- Total Hazardous Waste Generated
How Alphamab Oncology reduced the environmental impact of its waste?
Since 2021, Alphamab Oncology's total waste generation rose by 203.08%, but dropped by 24.05% in 2023, indicating a possible turning point driven by improved waste-reduction practices or production slowdowns.a
Over the same period, the share of hazardous waste in Alphamab Oncology's total output increased by 20.86%, including a further 1.15% rise in 2023, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.a
Overall, while Alphamab Oncology has recently reduced waste output, its hazardous waste share continues to rise, raising concerns about treatment efficiency or growing reliance on harmful materials despite short-term volume improvements.a